Rfg Advisory, LLC Bristol Myers Squibb CO Transaction History

Rfg Advisory, LLC

$3.18 Billion
Q3 2024

A detailed history of Rfg Advisory, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Rfg Advisory, LLC holds 17,191 shares of BMY stock, worth $992,952. This represents 0.03% of its overall portfolio holdings.

Number of Shares

17,191

Previous 18,917 9.12%

Holding current value

$992,952

Previous $785,000 13.25%

% of portfolio

0.03%

Previous 0.03%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	SELL	$39.66 - $51.75 $68,453 - $89,320	-1,726 Reduced 9.12%	17,191 $889,000
Q2 2024 Jul 15, 2024	SELL	$40.25 - $52.99 $133,509 - $175,767	-3,317 Reduced 14.92%	18,917 $785,000
Q1 2024 Apr 11, 2024	BUY	$47.98 - $54.4 $202,379 - $229,459	4,218 Added 23.41%	22,234 $1.21 Million
Q4 2023 Jan 25, 2024	BUY	$48.48 - $57.85 $51,582 - $61,552	1,064 Added 6.28%	18,016 $924,000
Q3 2023 Oct 16, 2023	BUY	$57.89 - $64.73 $118,442 - $132,437	2,046 Added 13.73%	16,952 $983,000
Q2 2023 Aug 03, 2023	SELL	$63.71 - $70.74 $32,874 - $36,501	-516 Reduced 3.35%	14,906 $953,000
Q1 2023 May 09, 2023	BUY	$65.71 - $74.53 $9,002 - $10,210	137 Added 0.9%	15,422 $1.07 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $102,240 - $121,067	-1,493 Reduced 8.9%	15,285 $1.1 Million
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $199 - $117,949	1,535 Added 10.07%	16,778 $1.34 Million
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $87,144 - $95,976	-1,200 Reduced 7.3%	15,243 $1.1 Million
Q1 2022 May 11, 2022	BUY	$61.48 - $73.72 $25,821 - $30,962	420 Added 2.62%	16,443 $1.2 Million
Q4 2021 Feb 02, 2022	BUY	$53.63 - $62.52 $163,035 - $190,060	3,040 Added 23.42%	16,023 $999,000
Q3 2021 Oct 19, 2021	SELL	$59.17 - $69.31 $14,319 - $16,773	-242 Reduced 1.83%	12,983 $768,000
Q2 2021 Jul 29, 2021	BUY	$61.91 - $67.42 $12,320 - $13,416	199 Added 1.53%	13,225 $884,000
Q1 2021 Apr 19, 2021	SELL	$59.34 - $66.74 $5,993 - $6,740	-101 Reduced 0.77%	13,026 $822,000
Q4 2020 Feb 02, 2021	BUY	$57.74 - $65.43 $19,169 - $21,722	332 Added 2.59%	13,127 $820,000
Q3 2020 Oct 13, 2020	SELL	$57.43 - $63.64 $10,969 - $12,155	-191 Reduced 1.47%	12,795 $771,000
Q2 2020 Aug 03, 2020	BUY	$54.82 - $64.09 $35,687 - $41,722	651 Added 5.28%	12,986 $764,000
Q1 2020 Apr 17, 2020	BUY	$46.4 - $67.43 $1,763 - $2,562	38 Added 0.31%	12,335 $688,000
Q4 2019 Jan 22, 2020	BUY	$49.21 - $64.19 $36,759 - $47,949	747 Added 6.47%	12,297 $789,000
Q3 2019 Nov 13, 2019	BUY	$42.77 - $50.71 $40,417 - $47,920	945 Added 8.91%	11,550 $586,000
Q2 2019 Aug 23, 2019	BUY	$44.62 - $49.34 $473,195 - $523,250	10,605 New	10,605 $482,000
Q2 2019 Aug 15, 2019	SELL	$44.62 - $49.34 $442,541 - $489,354	-9,918 Closed	0 $0
Q1 2019 Apr 25, 2019	SELL	$45.12 - $53.8 $17,280 - $20,605	-383 Reduced 3.72%	9,918 $477,000
Q4 2018 Feb 15, 2019	SELL	$48.76 - $63.23 $187,238 - $242,803	-3,840 Reduced 27.16%	10,301 $535,000
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $217,338 - $245,140	3,938 Added 38.6%	14,141 $878,000
Q2 2018 Jul 25, 2018	BUY	$50.53 - $62.98 $155,682 - $194,041	3,081 Added 43.26%	10,203 $565,000
Q1 2018 May 10, 2018	BUY	$59.92 - $68.98 $112,769 - $129,820	1,882 Added 35.92%	7,122 $450,000
Q4 2017 Feb 08, 2018	BUY	$59.94 - $65.35 $44,715 - $48,751	746 Added 16.6%	5,240 $324,000
Q3 2017 Nov 02, 2017	BUY	$55.23 - $63.74 $15,409 - $17,783	279 Added 6.62%	4,494 $288,000
Q2 2017 Aug 14, 2017	SELL	N/A	-207 Reduced 4.68%	4,215 $236,000
Q1 2017 Nov 01, 2017	BUY	N/A	4,422	4,422 $235,000

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rfg Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rfg Advisory, LLC with notifications on news.

Account